

Michael D Green

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9551749/publications.pdf>

Version: 2024-02-01

46
papers

5,448
citations

331538

21
h-index

243529

44
g-index

48
all docs

48
docs citations

48
times ranked

6952
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. <i>Nature</i> , 2019, 569, 270-274.	13.7	1,528
2	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. <i>Cancer Discovery</i> , 2019, 9, 1673-1685.	7.7	566
3	Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. <i>Nature Biotechnology</i> , 2014, 32, 84-91.	9.4	497
4	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	15.2	451
5	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	3.9	423
6	Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells. <i>Cell Stem Cell</i> , 2012, 10, 398-411.	5.2	358
7	Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells. <i>Nature Biotechnology</i> , 2011, 29, 267-272.	9.4	337
8	The in vitro generation of lung and airway progenitor cells from human pluripotent stem cells. <i>Nature Protocols</i> , 2015, 10, 413-425.	5.5	163
9	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. <i>Cancer Research</i> , 2019, 79, 3940-3951.	0.4	154
10	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2712-2726.	3.9	112
11	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	7.7	93
12	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. <i>Radiotherapy and Oncology</i> , 2018, 126, 68-74.	0.3	74
13	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. <i>Cancer Cell</i> , 2021, 39, 480-493.e6.	7.7	71
14	IFN γ signaling integrity in colorectal cancer immunity and immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 23-32.	4.8	57
15	The Liver's Immunity Nexus and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 5-12.	3.2	47
16	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 33-45.	4.8	47
17	Metabolism drives macrophage heterogeneity in the tumor microenvironment. <i>Cell Reports</i> , 2022, 39, 110609.	2.9	46
18	Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 673-681.	0.9	38

#	ARTICLE	IF	CITATIONS
19	Adjuvant Radiation Improves Recurrence-Free Survival and Overall Survival in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3743-3750.	1.8	35
20	Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 915-921.	2.3	27
21	Stem cells of the respiratory system: From identification to differentiation into functional epithelium. <i>BioEssays</i> , 2013, 35, 261-270.	1.2	24
22	Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 614.	1.7	23
23	Functional Adaptation in Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 236-244.	1.0	18
24	Close to Home: Employment Outcomes for Recent Radiation Oncology Graduates. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1017-1021.	0.4	16
25	Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e210980.	2.8	16
26	Contribution of Lipid Oxidation and Ferroptosis to Radiotherapy Efficacy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12603.	1.8	15
27	Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2022, 163, 35-41.	0.9	15
28	Novel approaches for immune reconstitution and adaptive immune modeling with human pluripotent stem cells. <i>BMC Medicine</i> , 2011, 9, 51.	2.3	10
29	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. <i>Journal of Clinical Medicine</i> , 2020, 9, 1973.	1.0	10
30	Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	10
31	Integrating radiomics into clinical trial design. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 339-346.	0.4	9
32	Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/cJUN-Dependent Manner. <i>Molecular Cancer Research</i> , 2021, 19, 1571-1582.	1.5	8
33	DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1137-1150.	1.5	8
34	De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 171, 55-63.	1.3	8
35	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39.		7
36	Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 437.e1-437.e9.	0.8	7

#	ARTICLE	IF	CITATIONS
37	The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. Pigment Cell and Melanoma Research, 2021, 34, 629-640.	1.5	6
38	Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis. Translational Oncology, 2022, 21, 101428.	1.7	6
39	Radiotherapy in the Multidisciplinary Management of Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 776-781.	2.3	5
40	Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. International Journal of Radiation Oncology Biology Physics, 2022, 113, 752-758.	0.4	5
41	Three discipline collaborative radiation therapy (3DCRT) special debate: We should treat all cancer patients with hypofractionation. Journal of Applied Clinical Medical Physics, 2020, 21, 7-14.	0.8	4
42	Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. International Journal of Radiation Oncology Biology Physics, 2021, 111, e38-e53.	0.4	2
43	Three discipline collaborative radiation therapy (3DCRT) special debate: The single most important factor in determining the future of SBRT is immune response. Journal of Applied Clinical Medical Physics, 2019, 20, 6-12.	0.8	1
44	Significance of radiation esophagitis: Conditional survival assessment in patients with non-small cell lung cancer. Journal of the National Cancer Center, 2021, 1, 31-38.	3.0	1
45	It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies. , 2021, 9, .		1
46	Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities. Immunotherapy, 2017, 9, 695-699.	1.0	0